EGFR and head and neck squamous cell carcinoma: We further validated PIK3C2A as a driver of EGFR inhibitor resistance by CellTiter‐Glo viability assays and investigated how the combination of the EGFR inhibitor with PIK3C2A knockout impacts HNSCC viability.